- Update on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel Therapeutics
-
Sang-Hak Lee
-
Endocrinol Metab. 2017;32(1):36-40. Published online January 19, 2017
-
DOI: https://doi.org/10.3803/EnM.2017.32.1.36
-
-
4,033
View
-
57
Download
-
11
Web of Science
-
10
Crossref
-
Abstract
PDFPubReader
In recent studies, the reported prevalence of heterozygous familial hypercholesterolemia (FH) has been higher than in previous reports. Although cascade genetic screening is a good option for efficient identification of affected patients, diagnosis using only clinical criteria is more common in real clinical practice. Cardiovascular risk is much higher in FH patients due to longstanding low density lipoprotein cholesterol (LDL-C) burden and is also influenced by other risk factors. Although guidelines emphasize aggressive LDL-C reduction, the majority of patients cannot reach the LDL-C goal by conventional pharmacotherapy. Novel therapeutics such as proprotein convertase subtilisin/kexin type 9 inhibitors have shown strong lipid lowering efficacy and are expected to improve treatment results in FH patients.
-
Citations
Citations to this article as recorded by
- Effectiveness and Safety of a Fixed-Dose Combination of Valsartan and Rosuvastatin (Rovatitan® Tablet) in Patients with Concomitant Hypertension and Hyperlipidemia: An Observational Study
Kwang Je Lee, Jae-Kean Ryu, Yun-Hyeong Cho, Won Yong Shin, Jeong Su Kim, Young Won Yoon, Ji Yong Jang, Won Ho Kim, Jong Wook Beom, Seok-Min Kang Drug Design, Development and Therapy.2023; Volume 17: 1047. CrossRef - Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
Brian Tomlinson, Nivritti Gajanan Patil, Manson Fok, Christopher Wai Kei Lam Endocrinology and Metabolism.2021; 36(2): 279. CrossRef - Identification and Functional Characterization of a Low-Density Lipoprotein Receptor Gene Pathogenic Variant in Familial Hypercholesterolemia
Hong-Yan Shu, Wei Zhang, Cong-Cong Zheng, Man-Yun Gao, Yong-Cun Li, Yan-Gang Wang Frontiers in Genetics.2021;[Epub] CrossRef - Gut Microbiota and Complications of Type-2 Diabetes
Camelia Oana Iatcu, Aimee Steen, Mihai Covasa Nutrients.2021; 14(1): 166. CrossRef - LDLR Gene Mutation p.Asp360His and Familial Hypercholesterolemia in a Mexican Community
Teresita De Jesús Hernández Flores, Juan Ramón González García, Yoaly Josefina Sánchez López, Norma Alejandra Vázquez Cárdenas, Ana Gabriela Colima Fausto, Sergio Yair Rodríguez Preciado, María Teresa Magaña Torres Archives of Medical Research.2020; 51(2): 153. CrossRef - A Rare Double Heterozygous Mutation in Low-Density Lipoprotein Receptor and Apolipoprotein B-100 Genes in a Severely Affected Familial Hypercholesterolaemia Patient
Lilla Juhász, István Balogh, László Madar, Beáta Kovács, Mariann Harangi Cureus.2020;[Epub] CrossRef - Efficacy and Safety of a Fixed-Dose Combination of Candesartan and Rosuvastatin on Blood Pressure and Cholesterol in Patients With Hypertension and Hypercholesterolemia: A Multicenter, Randomized, Double-Blind, Parallel Phase III Clinical Study
Kyoung Im Cho, Bo Hyun Kim, Yong Hyun Park, Jeong-Cheon Ahn, Sang Hyun Kim, Wook Jin Chung, Weon Kim, Il Suk Sohn, Jin Ho Shin, Yong Jin Kim, Kiyuk Chang, Cheol Woong Yu, Soe Hee Ahn, Seok Yeon Kim, Jae Kean Ryu, Jong Young Lee, Bum Kee Hong, Taek Jong Ho Clinical Therapeutics.2019; 41(8): 1508. CrossRef - Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia
Mary P. McGowan, Seyed Hamed Hosseini Dehkordi, Patrick M. Moriarty, P. Barton Duell Journal of the American Heart Association.2019;[Epub] CrossRef - Autosomal recessive hypercholesterolemia: Case report
Zaneta Petrulioniene, Urte Gargalskaite, Violeta Mikstiene, Rimvydas Norvilas, Egle Skiauteryte, Algirdas Utkus Journal of Clinical Lipidology.2019; 13(6): 887. CrossRef -
Q192R polymorphism in the
PON1
gene and familial hypercholesterolemia in a Saudi population
Khalid Khalaf Alharbi, May Salem Alnbaheen, Fawiziah Khalaf Alharbi, Rana M. Hasanato, Imran Ali Khan Annals of Saudi Medicine.2017; 37(6): 425. CrossRef
|